Diabetology International

, Volume 7, Issue 1, pp 12–15 | Cite as

Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report

  • Atsushi Goto
  • Hiroshi Noto
  • Mitsuhiko Noda
  • Kohjiro UekiEmail author
  • Masato Kasuga
  • Naoko Tajima
  • Ken Ohashi
  • Ryuichi Sakai
  • Shoichiro Tsugane
  • Nobuyuki Hamajima
  • Kazuo Tajima
  • Kohzoh Imai
  • Hitoshi Nakagama
Report of the committee


The Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer published its first report in July 2013 on the epidemiological assessment of the associations of diabetes with cancer risk/prognosis, the common risk factors for diabetes and cancer, and cancer risk associated with diabetes treatment The JDS/JCA Joint Committee continued its work to assess the role of glycemic control in the development of cancer in patients with diabetes. This review shows that high-quality evidence examining the association between glycemic control and cancer risk is lacking.


Diabetes Cancer Glucose control HbA1c Randomized controlled trials Observational studies 


Compliance with ethical standards

Conflict of interest

Hiroshi Noto received honoraria for manuscripts from Eli Lilly Japan K.K. Mitsuhiko Noda received scholarship grants from Takeda Pharmaceutical Company Limited and AstraZeneca K. K. Kohjiro Ueki received speaker honoraria from MSD K.K, scholarship grants from Takeda Pharmaceutical Company Limited, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sanofi K. K, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K, MSD K.K, Boehringer Ingelheim, Mitsubishi-Tanabe Pharma Corporation and courses endowed by MSD K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Naoko Tajima received speaker honoraria from Astellas Pharma Inc., MSD K.K, Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly Japan K.K, Boehringer Ingelheim and Novo Nordisk Pharma Ltd. Nobuyuki Hamajima received scholarship grants from Sugi Drugstore Co. Ltd. Kohzoh Imai received research grants from DeNA Life Science. Inc. Hitoshi Nakagama received research grants from Shimadzu Corporation and BioMimetics Sympathies Inc. Atsushi Goto, Masato Kasuga, Ken Ohashi, Ryuichi Sakai, Shoichiro Tsugane and Kazuo Tajima declare that they have no conflict of interest.


  1. 1.
    Goto A, Noto H, Noda M, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer, Second Report. J Japan Diabetes Soc. 2016;59(3):174–77. doi: 10.11213/tonyobyo.59.174 (In Japanese) Google Scholar
  2. 2.
    Kasuga M, Ueki K, Tajima N, et al. Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetol Int. 2013;4(2):81–96.CrossRefGoogle Scholar
  3. 3.
    Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocr Pract. 2011;17(4):616–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Sasazuki S, Charvat H, Hara A, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMedGoogle Scholar
  6. 6.
    Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011;54(7):1608–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefGoogle Scholar
  8. 8.
    Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54(1):25–31.CrossRefPubMedGoogle Scholar
  9. 9.
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–53.CrossRefGoogle Scholar
  10. 10.
    UK Prospective Diabetes Study. UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet. 1998;352(9131):854–65.CrossRefGoogle Scholar
  11. 11.
    The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterrans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMedGoogle Scholar
  13. 13.
    Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.CrossRefPubMedGoogle Scholar
  14. 14.
    Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35.CrossRefPubMedGoogle Scholar
  15. 15.
    Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–60.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg-Olofsson K, Gudbjornsdottir S. HbA1C and cancer risk in patients with type 2 diabetes–a nationwide population-based prospective cohort study in Sweden. PLoS One. 2012;7(6):e38784.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Onitilo AA, Stankowski RV, Berg RL, et al. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23(2):134–40.CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Diabetes Society and the Japanese Cancer Association 2016

Authors and Affiliations

  • Atsushi Goto
    • 1
  • Hiroshi Noto
    • 2
  • Mitsuhiko Noda
    • 3
  • Kohjiro Ueki
    • 4
    Email author
  • Masato Kasuga
    • 5
  • Naoko Tajima
    • 6
  • Ken Ohashi
    • 7
  • Ryuichi Sakai
    • 8
  • Shoichiro Tsugane
    • 9
  • Nobuyuki Hamajima
    • 10
  • Kazuo Tajima
    • 11
  • Kohzoh Imai
    • 12
  • Hitoshi Nakagama
    • 13
  1. 1.Tokyo Women’s Medical UniversityTokyoJapan
  2. 2.St. Luke’s International HospitalTokyoJapan
  3. 3.Department of Endocrinology and DiabetesSaitama Medical UniversitySaitamaJapan
  4. 4.Department of Diabetes and Metabolic Diseases, Graduate School of MedicineUniversity of TokyoTokyoJapan
  5. 5.National Center for Global Health and MedicineTokyoJapan
  6. 6.Jikei University School of MedicineTokyoJapan
  7. 7.Department of General Internal Medicine, Dentistry, and Oncologic EmergenciesNational Cancer Center HospitalTokyoJapan
  8. 8.Department of BiochemistryKitasato University School of MedicineSagamiharaJapan
  9. 9.National Cancer Center Research Center for Cancer Prevention and ScreeningTokyoJapan
  10. 10.Department of Healthcare AdministrationNagoya University Graduate School of MedicineNagoyaJapan
  11. 11.Department of Public Health and Occupational MedicineMie University Graduate School of MedicineTsuJapan
  12. 12.Center for Antibody and Vaccine Therapy, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  13. 13.National Cancer Center Research InstituteTokyoJapan

Personalised recommendations